Good News Alert! 11 Positive Things You Need to Know About
Results from a late-stage clinical trial have confirmed the effectiveness of Donanemab, an experimental Alzheimer's drug from drugmaker Eli Lilly, in slowing down cognitive decline among patients in the early stages of the ailment.